News

Conference Coverage

NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers

06/29/2023

Allison Casey

According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.

According to phase 3 data...

06/29/2023

Oncology

Conference Coverage

Novel FGFR TKI Demonstrated Efficacy and Safety for Patients With Advanced Intrahepatic Cholangiocarcinoma

06/02/2023

Allison Casey

The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.

The FGFR-selective tyrosine...

06/02/2023

Oncology

Milind Javle, MD, MD Anderson Cancer Center

Videos

The Changing Treatment Landscape of Cholangiocarcinoma

04/12/2023

At the 2023 Great Debates and Updates in GI Malignancies, Milind Javle, MD, discusses the recent developments in the treatment of patients with cholangiocarcinoma.

At the 2023 Great Debates and...

04/12/2023

Oncology

Videos

Recent Approvals for Cholangiocarcinoma Treatment

04/06/2023

While at the 2023 Great Debates and Updates in GI Malignancies meeting in Chicago, Milind Javle, MD, reviews the latest FDA approvals in the cholangiocarcinoma space.

While at the 2023 Great Debates...

04/06/2023

Oncology

Alison Schram, MD, Memorial Sloan Kettering Cancer Center

Videos

Targeting Class II/III Alterations in BRAF Inhibitors

03/16/2023

At 2023 ESMO Targeted Anticancer Therapies Congress, Alison Schram, MD, discusses the class II/III alterations of BRAF inhibitors.

At 2023 ESMO Targeted Anticancer...

03/16/2023

Oncology

Firas Baidoun, MD, Mayo Clinic - Florida

Videos

Neoadjuvant Chemotherapy Demonstrates Survival Benefit for Patients With Stage III Cholangiocarcinoma

03/06/2023

Firas Baidoun, MD, discusses an abstract presented at 2023 ASCO Gastrointestinal Cancers Symposium evaluating peri-operative chemotherapy for patients with non-metastatic cholangiocarcinoma.

Firas Baidoun, MD, discusses an...

03/06/2023

Oncology

Rachna Shroff, MD, University of Arizona Cancer Center

Videos

No Survival Benefit From Addition of Nab-paclitaxel to Gemcitabine-Cisplatin for Patients With Biliary Tract Cancers

01/26/2023

Rachna Shroff, MD, shares data from a phase 3 trial evaluating gemcitabine, cisplatin, and nab-paclitaxel for newly diagnosed, advanced biliary tract cancers.

Rachna Shroff, MD, shares data...

01/26/2023

Oncology

Conference Coverage

Nanvuranlat Demonstrated Clinical Activity for Advanced, Refractory Biliary Tract Cancers

01/20/2023

Allison Casey

According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...

According to a phase 2 trial...

01/20/2023

Oncology

News

Annual MRI for Patients With Primary Sclerosing Cholangitis Failed to Provide Long-Term Cholangiocarcinoma Survival Benefit

11/21/2022

Allison Casey

Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.

Among patients with primary...

11/21/2022

Oncology

News

Trastuzumab Biosimilar Plus FOLFOX Shows Promise for HER2-Positive Biliary Tract Cancers

11/10/2022

In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.

In a phase 2 trial, trastuzumab...

11/10/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology